Press releases

26 Jun 2023

Change in UCB’s Executive Committee

20 Jun 2023

UCB showcases commitment to transforming outcomes for people living with epilepsy and rare epileptic syndromes at European Pediatric Neurology Society (EPNS) Annual Congress

7 Jun 2023

UCB Receives New European Commission Approvals for BIMZELX[®]▼(bimekizumab) for the Treatment of Psoriatic Arthritis and Axial Spondyloarthritis

31 May 2023

New Long-Term Data on Bimekizumab in Psoriatic Arthritis and Axial Spondyloarthritis Presented at EULAR 2023

30 May 2023

UCB Showcases Commitment to Advancing Care in Immune-Mediated Inflammatory Diseases with 23 Abstracts at EULAR 2023

26 May 2023

Transparency notification FMR LLC

Press releases

Press releases

Search Press releases

Change in UCB’s Executive Committee

UCB showcases commitment to transforming outcomes for people living with epilepsy and rare epileptic syndromes at European Pediatric Neurology Society (EPNS) Annual Congress

UCB Receives New European Commission Approvals for BIMZELX[®]▼(bimekizumab) for the Treatment of Psoriatic Arthritis and Axial Spondyloarthritis

New Long-Term Data on Bimekizumab in Psoriatic Arthritis and Axial Spondyloarthritis Presented at EULAR 2023

UCB Showcases Commitment to Advancing Care in Immune-Mediated Inflammatory Diseases with 23 Abstracts at EULAR 2023

Transparency notification FMR LLC

Choose a Country

Hypothesize That! Discover our new science podcast, where science meets conjecture and curiosity

Publications - A dedicated space where we share a collection of our scientific peer-reviewed...

Pipeline - Check out our clinical development pipeline spanning several therapy areas

Hidradenitis Suppurativa – Learn more about Hidradenitis Suppurativa an inflammatory skin disease

WoCBA - Closing the gaps in research in the care of women of childbearing age with chronic diseases

Clinical studies – Click to find out more on our clinical studies

Integrated Annual Report 2024 - Click here to access the report

UCBCares® - Discover what UCBCares® is about and the services they offer

Driving innovation forward: UCB unveils new R&D facility

Global data show real-world effectiveness of romosozumab for patients at high fracture risk

BIMZELX[®] (bimekizumab-bkzx) five-year data at AAD 2025 showed sustained skin clearance and long...

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

UCB completes sale of established brands and updates 2024 financial guidance

Download center – Click here to view a collection of useful documents

Press releases

Search Press releases

Change in UCB’s Executive Committee

UCB showcases commitment to transforming outcomes for people living with epilepsy and rare epileptic syndromes at European Pediatric Neurology Society (EPNS) Annual Congress

UCB Receives New European Commission Approvals for BIMZELX[®]▼(bimekizumab) for the Treatment of Psoriatic Arthritis and Axial Spondyloarthritis

New Long-Term Data on Bimekizumab in Psoriatic Arthritis and Axial Spondyloarthritis Presented at EULAR 2023

UCB Showcases Commitment to Advancing Care in Immune-Mediated Inflammatory Diseases with 23 Abstracts at EULAR 2023

Transparency notification FMR LLC

Choose a Country